BioCardia Enters Agreement with BlueRock Therapeutics To Provide Enabling Catheter Biotherapeutic Delivery Product Candidates For BlueRock’s Cell Therapy To Treat Heart Failure
BioCardia®, Inc. (NASDAQ:BCDA), today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock's cell therapy product candidates for the treatment of
BioCardia Q2 EPS $(0.14) Beats $(0.25) Estimate, Sales $974.00K Up From $69.00K YoY
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 44 percent. This is a 30 percent increase over losses of $(0.20) per share from the same
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
BioCardia Earnings Preview
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement.
Analysts estimate that BioCardia will report an earnings per share (EPS) of $-0.25.
BioCardia Announces First Canadian Clinical Site For CardiAMP Cell Therapy Heart Failure Trial
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the